Anticardiolipin and Anti-β2-Glycoprotein-I Antibodies in Hypertensive Disorders of Pregnancy

Background tudy was undertaken in order to determine the frequency of anticardiolipin (aCL) and anti-β2-glycoprotein-I antibodies (anti-β2GP-I) in patients with hypertensive disorders of pregnancy. s died aCL (IgG and IgM) and IgG anti-β2GP-I by ELISA in the serum and IgG aCL and anti-β2GP-I in the urine of 125 women with hypertensive disorders of pregnancy (cases) (75 had preeclampsia, 25 had eclampsia, and 25 had chronic hypertension). One hundred and twenty seven normal women were used as controls. Antibody positivity was defined as above the 90th percentile of the controls. s nd no differences in frequency of serum anti-β2GP-I or serum and urinary aCL between cases and controls. In contrast, we found that frequency of IgG anti-β2GP-I was higher in the urine of cases (26.1%) compared to controls (9.4%, p = 0.001). Strength of association was stronger for urinary anti-β2-glycoprotein-I in women with preeclampsia (odds ratio [OR] = 4.3, 95% confidence limit [CI 95%] = 1.95–9.62, p <0.0001). Cases and the subgroup of preeclamptic patients also had higher titers of urinary IgG anti-β2GP-I than control women (p <0.0001). sions rk suggests that urine testing is necessary in order to ascertain whether antibodies to β2GP-I are associated with preeclampsia.